Regardless of all criticism of the intrigues over the approval of Pfizer’s experimental Covid vaccine, the fiddling with the US FDA to prevent the publication of study data and side effects, and questions about the general safety of mRNA vaccines, Pfizer CEO Bourla is calling for one second booster and an annual vaccination subscription for the general public.
As Report24 has reported several times in the past, there are massive and serious concerns about the effectiveness and safety of the experimental Covid vaccines. Especially the new mRNA vaccines (often also called “gene therapies”) are repeatedly targeted by scientists and critics, since in addition to the unknown long-term side effects there is already a questionable health cost-benefit ratio (see also these two most recent reports here and here). During the Pfizer CEO Albert Bourla on the CBS show “Face the Nation”. claimsthat “the protection we get from the third dose is good enough”, even “actually pretty good for hospitalization and death”, the reality is a little different.
Meanwhile, Bourla also admitted to CBS that “the protection doesn’t last very long” — paving the way for the next booster shot. And not only that: “So we’re not just trying to develop a vaccine that protects against all variants, including Omicron, but also one that protects for at least a year, and we’re working very hard on that right now.” Conversely, this means that people should pick up their gene injections every year so that Pfizer can, so to speak, collect money with a subscription. Pfizer is already assuming that it will be in 2022 a total of $54 billion thanks to Covid-19 to be able to implement. According to this, the mRNA vaccine Comirnaty should bring in $32 billion and the antiviral drug Paxlovid $22 billion. These are according to one Message the company’s “cash cows,” while other drugs fare poorly. No wonder, then, that the company relies on future “vaccination subscriptions”. There are hefty profits to be made here.
Given that many governments around the world are still willing to spend huge sums of money on these experimental vaccines, it can be assumed that this business model will continue to be profitable for Pfizer. An example of this: Austria. After initially wanting to refrain from a general vaccination requirement because the pressure from the population was too great, this should now be in September still come. Although panic is still being fueled and warnings of a possible new variant of the corona virus are being held, the fact that the turquoise-green federal government has a total of 42 million vaccine doses (primarily from Pfizer) for 2022 and 2023 is not the reason why the highly controversial vaccination requirement is being adhered to wants to order? The price: 841.8 million euros (20 euros per “shot”). A circumstance that also raises questions in relation to Pfizer’s lobbying activities. After all, that’s enough to vaccinate seven million people in Austria a total of six times – once every four months.